Choong-wae, Kaken enter into exclusive agreement for marketing of butenafine hydrochloride cream

Published: 2009-04-15 06:56:00

Updated: 2009-04-15 06:56:00

Choong-wae Shinyak, an affiliated company of Choongp-wae Holdings and Kaken Pharmaceutical Co. announced on April 13 that they have concluded a basic agreement on the exclusive marketing in Korea by Choong-wae of topical butenafine hydrochloride cream, a new benzylamine derivative

Butenafine is indicated for the topical treatment of tinea (pityriasis) versicolor due to M. furfur, as well as ...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.